AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29172994 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg daily for 5 months)
Number of subjects: 48
Study 29172994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28877705 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 102
Study 28877705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26363005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 610
Study 23998168 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs) prescribed, including amitriptyline, dextropropoxyphene, quinine, and benzodiazepines.
Number of subjects: 191
Study 23998168 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant depressive symptoms (Geriatric Depression Scale ≥5)
Number of subjects: 191
Study 23998168 — intervention group
Group type: COMPARATOR
Intervention: Comparison of inappropriate medication use between those with and without significant depressive symptoms
Number of subjects: 191
Study 21283922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.1% cream applied once daily for two weeks
Number of subjects: 25
Study 21283922 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied once daily for two weeks (control)
Number of subjects: 25
Study 21283922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.1% cream
Number of subjects: 25
Study 19722789 — intervention group
Group type: EXPERIMENTAL
Intervention: Submarginal free gingival grafts (SMFGGs)
Number of subjects: 55
Study 19722789 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal free gingival grafts (MFGGs)
Number of subjects: 55
Study 19722789 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated homologous sites)
Number of subjects: 55
Study 19722789 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated sites
Number of subjects: 55
Study 19722789 — intervention group
Group type: COMPARATOR
Intervention: Treated and untreated sites
Number of subjects: 55
Study 17549479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine at standard rate (1,200 mg/m2 over 30 min) + Carboplatin (AUC of 5 over 4 h)
Number of subjects: 42
Study 17549479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine at fixed dose rate (1,200 mg/m2 over 120 min) + Carboplatin (AUC of 5 over 4 h)
Number of subjects: 42
Study 15545310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 15545310 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 15545310 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin with ranitidine or omeprazole
Number of subjects: 0
Study 11684971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with light general anesthesia and postoperative epidural patient-controlled analgesia
Number of subjects: 168
Study 11684971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with light general anesthesia and postoperative intravenous patient-controlled analgesia
Number of subjects: 168
Study 11684971 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone with postoperative epidural patient-controlled analgesia
Number of subjects: 168
Study 11684971 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone with postoperative intravenous patient-controlled analgesia
Number of subjects: 168
Study 11684971 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia
Number of subjects: 168
Study 11684971 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with postoperative analgesia
Number of subjects: 168
Study 9831221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin 40 mg/daily
Number of subjects: 196
Study 9831221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 8008537 — intervention group
Group type: EXPERIMENTAL
Intervention: General ultrasound screening
Number of subjects: 11925
Study 8008537 — intervention group
Group type: COMPARATOR
Intervention: Selective ultrasound screening
Number of subjects: 11925
Study 8008537 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound screening
Number of subjects: 11925
Study 2245667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 44
Study 2245667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6251939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene
Number of subjects: 347
Study 6251939 — intervention group
Group type: COMPARATOR
Intervention: Dexon
Number of subjects: 347
Study 30624425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric mHealth app
Number of subjects: 98
Study 30624425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low literacy pediatric health book with video
Number of subjects: 98
Study 30624425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both book and app
Number of subjects: 98
Study 30624425 — intervention group
Group type: COMPARATOR
Intervention: Car-seat safety video and handout
Number of subjects: 98
Study 31247504 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid agonist treatment (OAT)
Number of subjects: 1283
Study 31247504 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid agonist treatment (non-OAT)
Number of subjects: 1283
Study 27866988 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% PSR with an advanced wake-time
Number of subjects: 18
Study 27866988 — intervention group
Group type: COMPARATOR
Intervention: Control (habitual bed- and wake-time)
Number of subjects: 18
Study 25431430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Number of subjects: 215
Study 25431430 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (primarily individual-based CBT)
Number of subjects: 215
Study 24251120 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise (RE)
Number of subjects: 23
Study 24251120 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise with superimposed vibration stimuli (RVE)
Number of subjects: 23
Study 24251120 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 23
Study 21444867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic external-beam radiotherapy (EBRT)
Number of subjects: 714
Study 21444867 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (NAT)
Number of subjects: 714
Study 19299776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 108
Study 19299776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 108
Study 19299776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 108
Study 19299776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 108
Study 19299776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75-300 mg
Number of subjects: 108
Study 17708607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 6 weeks
Number of subjects: 42
Study 17708607 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) therapy for 3 weeks
Number of subjects: 42
Study 17708607 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 42
Study 15087291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous ascorbic acid (AA)
Number of subjects: 0
Study 15087291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11600169 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation with Guided Imagery
Number of subjects: 116
Study 11600169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 9738388 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus BDP 400 micrograms/day
Number of subjects: 133
Study 9738388 — intervention group
Group type: COMPARATOR
Intervention: BDP 800 micrograms/day
Number of subjects: 133
Study 8048508 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 250 mg
Number of subjects: 20
Study 8048508 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 500 mg
Number of subjects: 20
Study 8048508 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 20
Study 8048508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2567740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg qid
Number of subjects: 19
Study 2567740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 19
Study 2567740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 182105 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing factor (TRF) 43 mg daily for 4 weeks
Number of subjects: 12
Study 182105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30621326 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Assistant-led after-school physical activity programme for 15 weeks
Number of subjects: 335
Study 30621326 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 335
Study 30621326 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Assistant-led after-school physical activity programme
Number of subjects: 335
Study 30621326 — intervention group
Group type: COMPARATOR
Intervention: Existing provision in the 12 schools
Number of subjects: 335
Study 27680604 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness CK7 staining
Number of subjects: 517
Study 27680604 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 status
Number of subjects: 517
Study 27680604 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent high-grade cytology
Number of subjects: 517
Study 27680604 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 IHC
Number of subjects: 517
Study 27680604 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradation/'top-down' CK7 pattern
Number of subjects: 517
Study 25887463 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing reduction manipulation
Number of subjects: 113
Study 25887463 — intervention group
Group type: COMPARATOR
Intervention: Control group (pain education)
Number of subjects: 113
Study 24283084 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of spinal plain bupivacaine only (Group B)
Number of subjects: 112
Study 24283084 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg plain bupivacaine with 25 mcg of fentanyl (Group BF)
Number of subjects: 112
Study 21904105 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg
Number of subjects: 100
Study 21904105 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 18798807 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1198
Study 18798807 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 1198
Study 18798807 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 1198
Study 18798807 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in pain levels
Number of subjects: 1198
Study 18798807 — intervention group
Group type: EXPERIMENTAL
Intervention: Time taken to return to normal activities after treatment
Number of subjects: 1198
Study 16421404 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 2.4 ml
Number of subjects: 82
Study 16421404 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (various doses: 0.3 ml, 0.6 ml, 1.2 ml, 2.4 ml)
Number of subjects: 82
Study 16421404 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 82
Study 15285725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled buffy-coat platelet components prepared in reduced (35%) plasma content
Number of subjects: 0
Study 15285725 — intervention group
Group type: COMPARATOR
Intervention: Platelet components suspended in 100% plasma
Number of subjects: 0
Study 15285725 — intervention group
Group type: COMPARATOR
Intervention: T-Sol control platelet components mixed with plasma
Number of subjects: 0
Study 11745947 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal median sensory latencies
Number of subjects: 77
Study 11745947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 9294681 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratometry-style readings (K)
Number of subjects: 208
Study 9294681 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-radial keratotomy (RK)
Number of subjects: 208
Study 9294681 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-excimer laser photorefractive keratectomy (PRK)
Number of subjects: 208
Study 8343473 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.4 mg/ml (0.04%) eye drops, four times a day for 2 weeks post-surgery
Number of subjects: 30
Study 8343473 — intervention group
Group type: COMPARATOR
Intervention: Bare sclera technique for pterygium excision
Number of subjects: 30
Study 3534140 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 38
Study 3534140 — intervention group
Group type: EXPERIMENTAL
Intervention: acyclovir
Number of subjects: 38
Study 30167757 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on day 1 and 200 mg twice on days 2-5)
Number of subjects: 12
Study 30167757 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 12
Study 30167757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26104432 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down treatment program (short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy)
Number of subjects: 79
Study 26104432 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient individual psychotherapy
Number of subjects: 79
Study 25588402 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel method
Number of subjects: 0
Study 25588402 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 0
Study 25588402 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium laser
Number of subjects: 0
Study 22836071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2-4 mg/day (PITA, n = 97)
Number of subjects: 189
Study 22836071 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10-20 mg/day (ATOR, n = 92)
Number of subjects: 189
Study 22836071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (n = 68)
Number of subjects: 189
Study 22836071 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (n = 67)
Number of subjects: 189
Study 22836071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (n = 18)
Number of subjects: 189
Study 22836071 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (n = 20)
Number of subjects: 189
Study 20831782 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine replacement every 3 days
Number of subjects: 362
Study 20831782 — intervention group
Group type: COMPARATOR
Intervention: Clinically indicated resite
Number of subjects: 362
Study 18778758 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-Form 1 (matrix)
Number of subjects: 10
Study 18778758 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-Form 2 (coated)
Number of subjects: 10
Study 18778758 — intervention group
Group type: COMPARATOR
Intervention: Prolopa HBS 125 (marketed product)
Number of subjects: 10
Study 18778758 — intervention group
Group type: EXPERIMENTAL
Intervention: Benserazide (inhibitor of extracerebral dopa decarboxylase)
Number of subjects: 10
Study 18778758 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (inhibitor of extracerebral dopa decarboxylase)
Number of subjects: 10
Study 16154437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin (HC) 1 mg intravenous weekly for 8 weeks
Number of subjects: 0
Study 16154437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin (CC) for 8 weeks
Number of subjects: 0
Study 16154437 — intervention group
Group type: COMPARATOR
Intervention: Crossover to alternate form (HC or CC)
Number of subjects: 0
Study 14559955 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing Disability in Alzheimer Disease (RDAD) program
Number of subjects: 153
Study 14559955 — intervention group
Group type: COMPARATOR
Intervention: Routine Medical Care (RMC)
Number of subjects: 153
Study 10765065 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5α-reductase inhibitor)
Number of subjects: 0
Study 10765065 — intervention group
Group type: EXPERIMENTAL
Intervention: GI198745 (dual 5α-reductase inhibitor)
Number of subjects: 0
Study 8895267 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 44
Study 8895267 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl anesthesia
Number of subjects: 44
Study 8895267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 44
Study 2049752 — intervention group
Group type: EXPERIMENTAL
Intervention: POG protocol 8303 (four-drug systemic reinduction: prednisone, vincristine, daunorubicin, and asparaginase; brief intensive consolidation with teniposide and cytarabine; continuation chemotherapy with weekly rotating drug pairs; bilateral testicular radiation (2600 cGy); intrathecal chemoprophylaxis every 4 to 6 weeks)
Number of subjects: 38
Study 6589968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation and chemotherapy
Number of subjects: 50
Study 6589968 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 50
Study 6589968 — intervention group
Group type: COMPARATOR
Intervention: Longer duration of chemotherapy
Number of subjects: 50
Study 6589968 — intervention group
Group type: COMPARATOR
Intervention: Younger age at the time of radiation
Number of subjects: 50
Study 6589968 — intervention group
Group type: COMPARATOR
Intervention: Dose of cranial radiation, concomitant intrathecal methotrexate therapy, and duration of therapy
Number of subjects: 50
Study 31533863 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 250
Study 31533863 — intervention group
Group type: COMPARATOR
Intervention: Not surgery (control)
Number of subjects: 250
Study 29785146 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma question prompt list with video intervention
Number of subjects: 359
Study 29785146 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 359
Study 27621597 — intervention group
Group type: COMPARATOR
Intervention: AZD1981 1,000 mg bid
Number of subjects: 719
Study 27621597 — intervention group
Group type: COMPARATOR
Intervention: AZD1981 50 mg bid
Number of subjects: 719
Study 27621597 — intervention group
Group type: COMPARATOR
Intervention: AZD1981 400 mg bid
Number of subjects: 719
Study 24355040 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg
Number of subjects: 211
Study 23026854 — intervention group
Group type: EXPERIMENTAL
Intervention: Webcam intervention (telepsychiatry)
Number of subjects: 167
Study 23026854 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 167
Study 21051656 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg lasofoxifene
Number of subjects: 8556
Study 21051656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study 18052570 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 4 mg/day for 1 year)
Number of subjects: 159
Study 18052570 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2 to 4 mg/day for 1 year)
Number of subjects: 159
Study 18052570 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 159
Study 18052570 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 159
Study 18052570 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol
Number of subjects: 159
Study 16047123 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg) administered intravenously 3 min prior to treadmill stress
Number of subjects: 86
Study 16047123 — intervention group
Group type: COMPARATOR
Intervention: No atropine administered (Control)
Number of subjects: 86
Study 12475854 — intervention group
Group type: EXPERIMENTAL
Intervention: Five different bilevel pressure home ventilators
Number of subjects: 28
Study 9565927 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (ET) for 6 months, including lumbar extension (MedX) 1 day/week and variable resistance exercises (Nautilus) 2 days/week.
Number of subjects: 14
Study 9565927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training) for 6 months.
Number of subjects: 14
Study 9565927 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (ET) for 6 months.
Number of subjects: 14
Study 7625665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 0
Study 7625665 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (OPV)
Number of subjects: 0
Study 7625665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diphtheria and tetanus toxoids and pertussis vaccine with IPV
Number of subjects: 0
Study 2515822 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (acylated streptokinase, intravenous bolus of 30 units in 4 minutes)
Number of subjects: 100
Study 2515822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2515822 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 100
Study 823725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamol
Number of subjects: 0
Study 823725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 823725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 823725 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium
Number of subjects: 0
Study 31727650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia Awareness Restoration Programme despite optimised care (HARPdoc)
Number of subjects: 28
Study 31727650 — intervention group
Group type: COMPARATOR
Intervention: Blood Glucose Awareness Training (BGAT)
Number of subjects: 28